Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications

MLA

E. Caronna, et al. “Safety of Anti-CGRP Monoclonal Antibodies in Patients with Migraine during the COVID-19 Pandemic: Present and Future Implications.” Neurología, vol. 36, no. 8, Oct. 2021, pp. 611–17. EBSCOhost, https://doi.org/10.1016/j.nrl.2021.03.003.

APA

E. Caronna, V. José Gallardo, A. Alpuente, M. Torres-Ferrus, N.M. Sánchez-Mateo, J. Viguera-Romero, A.C. López-Veloso, A. López-Bravo, A.B. Gago-Veiga, P. Irimia Sieira, J. Porta-Etessam, S. Santos-Lasaosa, & P. Pozo-Rosich. (2021). Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications. Neurología, 36(8), 611–617. https://doi.org/10.1016/j.nrl.2021.03.003

Chicago

E. Caronna, V. José Gallardo, A. Alpuente, M. Torres-Ferrus, N.M. Sánchez-Mateo, J. Viguera-Romero, A.C. López-Veloso, et al. 2021. “Safety of Anti-CGRP Monoclonal Antibodies in Patients with Migraine during the COVID-19 Pandemic: Present and Future Implications.” Neurología 36 (8): 611–17. doi:10.1016/j.nrl.2021.03.003.